Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HCV HIV Clear all
Completed No phase listed Observational

HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)

NCT00339430
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 22, 2026, 10:21 PM EDT
Withdrawn Phase 4 Interventional

A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C

NCT02206932
View directory record Official record
Conditions
Hepatitis C, Chronic, HIV CDC Category A1
Interventions
Sofosbuvir + Simeprevir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 22, 2026, 10:21 PM EDT
Completed No phase listed Observational

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

NCT01296529
View directory record Official record
Conditions
HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Sep 22, 2026, 10:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk Assessment of Long-Haul Truck Drivers

NCT00381992
View directory record Official record
Conditions
Gonorrhea, Chlamydia Infections, Hepatitis B, Hepatitis C, Diabetes Mellitus, Hypertension, Obesity, HIV Infections, Hyperlipidemia
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 22, 2026, 10:21 PM EDT
Active, not recruiting Not applicable Interventional

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

NCT06316739
View directory record Official record
Conditions
HIV Infections, HCV, Overdose
Interventions
Ganchero intervention
Behavioral
Lead sponsor
North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 22, 2026, 10:21 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV

NCT01040039
View directory record Official record
Conditions
HIV Infections, Hepatitis C Virus
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Sep 22, 2026, 10:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Setting Focus Overdose Prevention Intervention

NCT05320835
View directory record Official record
Conditions
HIV Infections, HCV, Drug Overdose
Interventions
HIV, HCV and overdose prevention
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

NCT02032888
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Not applicable Interventional Results available

Coaching for HCV and HIV

NCT04314414
View directory record Official record
Conditions
Hepatitis C, HIV Infections, Opioid-use Disorder
Interventions
PRC brief motivational interview intervention, Phone contact
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 22, 2026, 10:21 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking

NCT07264582
View directory record Official record
Conditions
HIV Testing, STI, HCV, Overdose, Drug
Interventions
Sex Trafficking Survivor-Developed Digital Crowdsourced Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 22, 2026, 10:21 PM EDT
Completed No phase listed Observational

To Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C, Along With Associated Risk Behaviors, in Patients With Severe Mental Illness (SMI).

NCT00007709
View directory record Official record
Conditions
Hepatitis C, HIV Infections, Mental Disorders
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Sep 22, 2026, 10:21 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

NCT06730555
View directory record Official record
Conditions
HIV Infections
Interventions
ACCESS Intervention, Control Group
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 22, 2026, 10:21 PM EDT
Completed No phase listed Observational

Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality

NCT02427204
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

UCLA-Amity Parolee Health Promotion Study

NCT01844414
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV, Drug Addiction
Interventions
Parolee Comprehensive Care + Phone Coach, Parolee Brief HBV Program + Phone Coach, Usual Care Group
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Acute Hepatitis C Virus in HIV Co-Infection

NCT00845676
View directory record Official record
Conditions
Hepatitis C, Human Immunodeficiency Virus, HIV Infections
Interventions
Pegylated interferon alfa-2a + Ribavirin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Sep 22, 2026, 10:21 PM EDT
Terminated No phase listed Observational Results available

Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection

NCT01182298
View directory record Official record
Conditions
Hepatitis C, HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

NCT01471574
View directory record Official record
Conditions
Hepatitis C, Genotype 1
Interventions
Daclatasvir, Ribavirin, PEG-Interferon alfa 2a
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 22, 2026, 10:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

NCT01447680
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection, Hepatitis C
Interventions
Not listed
Lead sponsor
G & W Laboratories Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Douglasville, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Sep 22, 2026, 10:21 PM EDT
Terminated Phase 3 Interventional Results available

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

NCT00678587
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

NCT02707601
View directory record Official record
Conditions
HIV-1 Infection, HCV Infection
Interventions
E/C/F/TAF, F/R/TAF, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Science Aspects of Rapid Test Acceptance

NCT01317784
View directory record Official record
Conditions
HIV, Hepatitis C, Hepatitis B, Syphilis
Interventions
Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis, HIV only
Device
Lead sponsor
California State University, Long Beach
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Not applicable Interventional

Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir

NCT02588287
View directory record Official record
Conditions
Hepatitis C and HIV Coinfection
Interventions
Blood draws for tenofovir PK, renal function
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV

NCT02124044
View directory record Official record
Conditions
HIV-HCV
Interventions
Asunaprevir and Daclatasvir, Asunaprevir and Daclatasvir with BMS-791325
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 22, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

NCT01482767
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 22, 2026, 10:21 PM EDT